NW Bio Featured In Presentations At the American Association for Cancer Research Annual Meeting
DCVax-L and DCVax-Direct Both To Be the Subject of Presentations Today
BETHESDA, MD, April 20, 2015 — Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that its clinical programs with DCVax-L for Glioblastoma multiforme (GBM) brain cancer, and with DCVax-Direct for all types of inoperable solid tumors, will be featured in presentations on Monday, April 20, 2015, at the American Association for Cancer Research Annual Meeting 2015 taking place in Philadelphia.
Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present a poster on the DCVax-L program, entitled Prolonged Survival In Patients With Recurrent Glioblastoma Multiforme Who Are Treated With Tumor Lysate-Pulsed Autologous Dendritic Cells. This presentation will take place in Section 26 of Halls B–E at the Pennsylvania Convention Center from 1:00 p.m. to 5:00 p.m. on Monday, April 20. The presentation will include further details about the subgroups within the Informational Arm.
Dr. Bosch will also make an Exhibitor Spotlight Presentation on Monday, April 20 from 3:00 p.m. to 3:30 p.m. in Exhibitor Spotlight Theater B, located near the poster presentation area in Halls B–E at the Pennsylvania Convention Center. Dr. Bosch will discuss NW Bio’s DCVax platform technology in a presentation entitled Clinical Development of Dendritic Cell-Based Therapies for Cancer. He will then return to the Company’s poster presentation area to complete the poster session.
The Clinical Trial Investigator at MD Anderson will present a poster on the DCVax-Direct program, entitled Clinical and Immunopathological Effects Following Image-Guided Intratumoral Injection Of Activated, Autologous Dendritic Cells In Patients With Advanced Solid Cancers. The poster will provide information about immune responses in the patients in the Phase I trial overall, as well as case study information. This presentation will take place in Section 26 of Halls B–E of the Convention Center, from 1:00 p.m. to 5:00 p.m. on Monday, April 20 (the same Hall and time period as Dr. Bosch’s poster presentation).
Both posters will be available on the Company’s website at www.nwbio.com.
The American Association for Cancer Research Annual Meeting 2015 highlights the latest discoveries in every area of cancer research, and provides an opportunity for investigators to share their insights. This year’s meeting theme is “Bringing Cancer Discoveries to Patients.”
“We are pleased to have an opportunity to present information about both our DCVax-L and DCVax-Direct clinical programs at this prestigious research conference,” commented Linda Powers, CEO of NW Bio. “In line with the theme of this year’s AACR meeting, we look forward to being able to bring DCVax dendritic cell therapies to patients as a potential new treatment option at the forefront of immune therapies for cancer.”
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead program is a 348-patient Phase III trial in newly diagnosed glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” The Company is underway with a 60-patient Phase I/II trial of DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression. Enrollment has been completed for the Phase I portion of the trial. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. NWBio conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all glioma (brain cancer) patients outside the clinical trial.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company’s ongoing ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS:
Les Goldman
202-841-7909
Michael Meehan
202-262-9081
Farrell Kramer (Media)
212-710-9685
